Biocept intends to become Thermo Fisher Scientific’s “Center of Excellence” for oncology-focused liquid biopsy efforts as part of a commercial collaboration by the companies. [© AlexRaths/iStock]

First “Tumor Uninformed” Cancer Recurrence Test Evaluated at Mass General

Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. The researchers at MGH and Guardant Health evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection.
Genetic research, conceptual illustration

Agendia to Distribute Inivata’s RaDaR MRD and Cancer Recurrence LBx in U.S. and Europe

The deal comes as Inivata anticipates forthcoming reimbursement decisions for the test and availability in the U.S. market in 2022.

Sanger Institute Improves NanoSeq Method to Detect New Mutations in Non-Dividing Cells

NanoSeq, a new and carefully refined form of duplex sequencing developed at the Wellcome Sanger Institute, is highly accurate and can detect single-cell mutations, which could allow early detection of diseases such as cancer.
Sick woman with Long COVID lying in bed

Gene Expression Changes Could Be Behind Long-Haul COVID-19 Symptoms

Exposure to the SARS-CoV-2 spike protein alone was enough to change baseline gene expression in airway cells in early stage research, suggesting a possible cause for long COVID symptoms.
Geisinger Health will begin offering DNA sequencing to patients as part of its routine clinical care. [iStock/Mark Bowden]

Mismatch Repair Algorithm Could Help Personalize Cancer Care

An algorithm called MMRDetect, designed by University of Cambridge researchers, can detect tumors that have mismatch repair mutations that should make them more vulnerable to treatment with immune checkpoint inhibitors.
A new technique to cheaply and rapidly create sets of DNA fragments that include all possible genetic variants will help scientists distinguish between genetic variants linked to disease and those that are innocuous. [Michael Worful]

More than 500 Structural Variants Linked to Hereditary Cancer and Cardiovascular Disorders Identified

The findings provide a better understanding of how structural variants can be detected in an individual’s genome and can help advance how individual risk for some diseases is calculated from genomic data.
COVID-19 antigen test

COVID-19 Testing Moves Towards Pooled and Rapid At-Home Tests

In line with national vaccination efforts in the U.S., COVID-19 testing is now moving towards pooled RT-PCR tests, with prompting from the FDA. Increased use of home testing is also being encouraged and evaluated for potential wider rollout by the CDC and NIH, with a view to reducing community transmission.

Sense Biodetection Raises $50M in Series B Financing toward COVID-19 Test, Dx Portfolio

Sense Biodetection has completed a $50 million Series B financing, with the molecular diagnostics company saying it will use the proceeds to accelerate the launch of its VerosTM COVID-19 test, and further develop a portfolio of instrument-free, rapid molecular tests.

Computational Tool Can Map Gene Expression in Space

Swiss scientists have developed a computational algorithm known as ‘Tomographer’ that can visualize and map gene expression in organs using tissue measurement and messenger RNA data.

Outgoing ACMG President Resigns after Firestorm Over Racial Remarks

Gregg’s reference to diverse populations by colors “was a serious mistake that caused pain and distress for many, including ACMG leadership,” the ACMG declared in a letter co-signed by its new President Marc S. Williams, M.D., and CEO, Maximilian Muenke, M.D.


Scroll Up